Table 4.

TTF and OS in patient subgroups.

Median time-to-treatment failure, months (95% CI)
	Any TKI n = 246		First-generation TKIs n = 106		Afatinib n = 132
All patients	9.9 (7.8-11.6)		8.8 (6.4-10.7)		11.3 (8.5-14.9)
Mutation category
Major uncommon	n = 179	11.3 (9.2-14.3)	n = 80	9.8 (7.6-12.9)	n = 94	14.3 (10.5-17.8)
Compound	n = 82	12.3 (8.5-15.5)	n = 32	12.4 (7.4-27.9)	n = 46	12.6 (6.9-15.7)
Others	n = 21	7.4 (2.1-12.8)	n = 12	7.3 (0.6-12.6)	n = 9	10.8 (0.2-17.9)
Exon 20 insertion	n = 29	5.5 (2.9-10.6)	n = 10	5.2 (1.4-9.6)	n = 18	8.3 (3.1-18.5)
T790M	n = 17	2.8 (2.1-7.4)	n = 4	2.1 (0.9–2.3)	n = 11	5.7 (1.9-12.6)
Baseline brain metastases (major uncommon)
No (n= 162)	10.7 (9.1-14.2)		—		—
Yes (n= 17)	17.3 (7.7-24.5)		—		—
ECOG PS (major uncommon)
<2 (n = 122)	11.5 (8.5-14.7)		—		—
≥2 (n = 20)	8.6 (4.6-15.7)		—		—
Overall survival, months (95% CI)
All patients	24.4 (20.2-28.2)		24.2 (16.8-31.3)		24.5 (20.8-27.4)
Mutation category
Major uncommon	n = 179	25.7 (19.7-30.2)	n = 80	28.5 (18.6-34.7)	n = 94	24.5 (18.4-28.6)
Compound	n = 82	28.7 (22.5-33.0)	n = 32	31.3 (15.6-80.1)	n = 46	23.4 (16.0-34.5)
Others	n = 21	13.4 (5.9–24.8)	n = 12	12.8 (3.7-55.8)	n = 9	20.2 (0.3-24.8)
Exon 20 insertion	n = 29	22.5 (14.3-49.7)	n = 10	21.0 (1.7-62.4)	n = 18	22.5 (9.9–NR)
T790M	n = 17	32.7 (11.1-83.2)	n = 4	14.2 (11.1-83.2)	n = 11	NR (10.3–NR)
Baseline brain metastases (major uncommon)
No (n = 162)	25.7 (19.4-30.2)		—		—
Yes (n = 17)	33.9 (11.5-49.6)		—		—
ECOG PS (major uncommon)
<2 (n = 122)	28.5 (19.7-34.5)		—		—
≥2 (n = 20)	14.3 (9.1-23.4)		—		—

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; NR, not reported.